Research programme: ovarian cancer therapies - Curie Institute/Sanofi
Latest Information Update: 16 Jul 2016
At a glance
- Originator Curie Institute; Sanofi
- Class
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Ovarian cancer
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for research development in Ovarian-cancer in France
- 19 Jun 2013 Early research in Ovarian cancer in France (unspecified route)